Tricyclic Isatin Derivatives as Anti-Inflammatory Compounds with High Kinase Binding Affinity
Molecules · 2025
DOI: 10.3390/molecules30142914 ↗At a glance
Journal article in Molecules, 2025. Written by Alexander V Uvarov and 3 co-authors. Institution: Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia. Major MEDLINE topics: Anti-Inflammatory Agents, Isatin, Protein Kinase Inhibitors. Cited 3 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY 4.0). Funded by: Russian Science Foundation, National Institutes of Health IDeA Program, Montana State University Agricultural Experiment Station.
Abstract (original language)
Oximes have been reported to exhibit useful pharmaceutical properties, including compounds with anticancer, anti-arthritis, antibacterial, and neuroprotective activities. Many oximes are kinase inhibitors and have been shown to inhibit various kinases. Herein, a panel of oxime derivatives of tricyclic isatins was synthesized and evaluated for inhibition of cellular inflammatory responses and binding affinity to several kinases. Compounds 5a and 5d (a.k.a. NS-102), which have an unsubstituted oxime group, inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) transcriptional activity in human THP-1Blue monocytic cells and interleukin-6 (IL-6) production in human MonoMac-6 monocytic cells, with IC50 values in the micromolar range. These compounds also inhibited LPS-induced production of several other proinflammatory cytokines, including IL-1α, IL-1β, monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF) in MonoMac-6 cells. Compounds 5a and 5d exhibited nanomolar/submicromolar binding affinity toward several kinase targets. The most potent inhibitor, 5d (3-(hydroxyimino)-5-nitro-1,3,6,7,8,9-hexahydro-2H-benzo[g]indol-2-one), demonstrated high binding affinity for 12 kinases, including DYRK1A, DYRK1B, PIM1, Haspin, HIPK1-3, IRAK1, NEK10, and DAPK1-3. Molecular modeling suggested modes of binding interaction of selected compounds in the DYRK1A and PIM1 catalytic sites that agreed with the experimental binding data. Our results demonstrate that tricyclic isatin oximes could be potential candidates for developing anti-inflammatory drugs with neuroprotective effects for treating neurodegenerative diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia.
- Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.
ORCID profiles: Mark T Quinn, Andrei I Khlebnikov
Funding
- Russian Science Foundation
- National Institutes of Health IDeA Program
- Montana State University Agricultural Experiment Station
Cite
APA
Uvarov, A. V., Schepetkin, I. A., Quinn, M. T., & Khlebnikov, A. I. (2025). Tricyclic Isatin Derivatives as Anti-Inflammatory Compounds with High Kinase Binding Affinity. Molecules. https://doi.org/10.3390/molecules30142914
Vancouver
Uvarov AV, Schepetkin IA, Quinn MT, Khlebnikov AI. Tricyclic Isatin Derivatives as Anti-Inflammatory Compounds with High Kinase Binding Affinity. Molecules. 2025. doi:10.3390/molecules30142914
BibTeX
@article{Uvarov2025,
author = {Uvarov, Alexander V and Schepetkin, Igor A and Quinn, Mark T and Khlebnikov, Andrei I},
title = {Tricyclic Isatin Derivatives as Anti-Inflammatory Compounds with High Kinase Binding Affinity},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30142914}
}
EUVIMED